Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals

Table 2 Characteristics of chronic hepatitis C patients after achieving sustained virological response 12 comparing those with and without steatosis n (%)

	Patients without steatosis(CAP < 248 dB/m) (n = 53)	Patients with steatosis(CAP ≥ 248 dB/m) (n = 48)	P1 value
Demographics
Male	25 (47)	27 (56)	NS
Age (yr, mean ± SD)	59.4 ± 11.6	60.9 ± 9.4	NS
White	18 (34)	18 (38)	NS
Hispanic	14 (26)	12 (25)	NS
Clinical
Hypertension	25 (47.2)	20 (41.7)	NS
Dyslipidemia	3 (5.7)	5 (10.4)	0.048
Type 2 diabetes	4 (7.5)	9 (18.7)	0.04
Anthropometric (mean ± SD)
Body mass index (kg/m2)	26.1 ± 6.9	28.9 ± 6.6	0.049
Weight (Lbs.)	161.0 ± 33.4	172.7 ± 44.5	0.005
Hepatology and viral hepatitis panel (mean ± SD)
AST (U/L)	20.2 ± 5.4	22.9 ± 9.8	NS
ALT (U/L)	15.3 ± 5.5	20.4 ± 16.5	0.048
Alkaline phosphatase (U/L)	70.7 ± 28.2	71.3 ± 19.4	NS
Albumin (g/dL)	4.3 ± 0.2	4.5 ± 0.6	NS
Bilirubin, total (mg/dL)	0.6 ± 0.3	0.6 ± 0.2	NS
Other laboratory studies (mean ± SD)
Total cholesterol (mg/dL)	184.8 ± 35.1	179 ± 37.2	NS
HDL cholesterol (mg/dL)	57.6 ± 18.6	50.8 ± 17.0	NS
LDL cholesterol (mg/dL)	102.6 ± 33.2	100.7 ± 31.5	NS
Triglycerides (mg/dL)	109.7 ± 63.9	138.9 ± 77.9	0.05
HbA1c (%)	5.7 ± 0.6	6.0 ± 0.9	NS
Fasting serum glucose (mg/dL)	96.5 ± 11.1	107.8 ± 30.5	0.023
FibroScan (mean ±SD)
Fibrosis Score (kPa)	5.3 ± 1.6	7.0 ± 4.8	0.0013
CAP (dB/m)	212.4 ± 29.0	296.3 ± 37.4	< 0.0001
% of patient with fibrosis score of (≥ 7 kPa)	0%	6.25%	0.066

¹P values (2-sided) determined from either a Fisher’s exact test for categorical variables or t-test for continuous variables. CAP: Controlled attenuation parameter; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; HDL: High density lipoprotein; LDL: Low density lipoprotein; CAP: Controlled attenuation parameter.